Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION IN the Treatment of DEPRESSION

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by St. Lucas Andreas Ziekenhuis Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
St. Lucas Andreas Ziekenhuis Hospital
ClinicalTrials.gov Identifier:
NCT00220610
First received: September 13, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted

September 13, 2005
September 13, 2005
May 2004
Not Provided
  • To determine the depression (and so the effect of the treatment)we use the 10-item Montgomery Asberg Depression Rating Scale (MADRS)and we measure before tms (T=0), at week 1 (T=1), at week 2 (T=2), at week 4 (T=3), at week 8 (T=4), at week 14 (T=5)
  • Besides the MADRS we use the BDI (Beck depression Inventory, the Hamillton deppression and anxiety scale)
Same as current
No Changes Posted
  • -Changes in anxiety
  • -.Autonomic changes
  • -.changes in the emotioneal attention, in the emotional memory en in de emotional recognition.
  • -.Biochemical changes
  • -.Changes in the EEG
  • >> measured before tms and after (at T=0 and T=2)
Same as current
Not Provided
Not Provided
 
REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION IN the Treatment of DEPRESSION
Right Parietal Inhibition With rTMS in the Treatment of Depression

Subjects received rTMS daily on 10 consecutive weekdays (five sessions per week), during 20 minutes per session.During the rTMS session, the coil was centered flat over the right parietal cortex.

We follow the patient during 12 weeks after the 2 weeks of tms (follow-up period) to measure the depression with different rating scales.

We hypothesized that rTMS has a positive effect in the treatment of depression

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Depression
Device: Transcranial magnetic stimulation
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
40
December 2006
Not Provided

Inclusion Criteria:

  • In and outpatients aged between 16 and 65 who met DSM-IV criteria for major depressive episode, and who had a score of 25 or higher on the 10-item Montgomery Asberg Depression Rating Scale (MADRS) were included

Exclusion Criteria:

  • A history of epilepsy and any other medical disorder that should preclude the administration of rTMS. Only SSRI's, Mirtazapine and Promethazine as psychotropic medication was accepted if the dosage of antidepressive medication had not been changed for 6 weeks, and if the dosage of Promethazine had not been changed for 2 weeks prior to inclusion. Antidepressive medication had to remain stable during the 14 weeks of the study.

Furthermore: schizophrenic disorder, a piece if metal in the brain, pacemaker and left-handed patients.

Both
16 Years to 65 Years
No
Contact: Judith van der Riet, Drs. 0031-20-5108562 j.vanderriet@slaz.nl
Netherlands
 
NCT00220610
CCMO03.3741/SH/P03.1231L
Not Provided
Not Provided
St. Lucas Andreas Ziekenhuis Hospital
Not Provided
Study Director: G.F Koerselman, prof. dr. st Lucas Andreas Ziekenhuis
St. Lucas Andreas Ziekenhuis Hospital
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP